GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Plus Therapeutics Inc (STU:XMP0) » Definitions » Institutional Ownership

Plus Therapeutics (STU:XMP0) Institutional Ownership : 1.16% (As of Apr. 24, 2025)


View and export this data going back to . Start your Free Trial

What is Plus Therapeutics Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Plus Therapeutics's institutional ownership is 1.16%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Plus Therapeutics's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Plus Therapeutics's Float Percentage Of Total Shares Outstanding is 34.04%.


Plus Therapeutics Institutional Ownership Historical Data

The historical data trend for Plus Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Plus Therapeutics Institutional Ownership Chart

Plus Therapeutics Historical Data

The historical data trend for Plus Therapeutics can be seen below:

2024-06-30 2024-07-31 2024-08-31 2024-09-30 2024-10-31 2024-11-30 2024-12-31 2025-01-31 2025-02-28 2025-03-31
Institutional Ownership 0.98 0.98 0.94 1.08 1.17 1.17 1.16 1.16 1.16 1.16

Plus Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Plus Therapeutics Business Description

Traded in Other Exchanges
Address
2710 Reed Road, Suite 160, Houston, TX, USA, 77051
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).

Plus Therapeutics Headlines

No Headlines